Trial Profile
A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jan 2023
Price :
$35
*
At a glance
- Drugs Iltamiocel (Primary)
- Indications Stress incontinence; Urinary incontinence
- Focus Registrational; Therapeutic Use
- Acronyms IND2
- Sponsors Cook MyoSite
- 13 Sep 2021 Results (n=75) of women with persistent or recurrent stress urinary incontinence following surgery, presented at the 116th Annual Meeting of the American Urological Association
- 13 Sep 2021 Results evaluating efficacy and safety of AMDC-USRcompared to PBO for SUI treatment presented at the 116th Annual Meeting of the American Urological Association
- 18 Nov 2020 Status changed from active, no longer recruiting to completed.